1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Pfizer Breast Cancer Drug Could Fill Void Left By Avastin Withdrawal

 
• By Shirley Haley

Pfizer’s novel oral CDK 4/6 inhibitor PD-03392991, in combination with letrozole, delivered a statistically and clinically significant increase in median progression-free survival for women with advanced ER+/HER2- breast cancer, according to interim Phase II data presented Dec. 5 at the San Antonio Breast Cancer Symposium.

SAN ANTONIO – Pfizer Inc. is headed into Phase III testing with a novel cell synthesis blocking agent that worked in combination with aromatase inhibitor letrozole in Phase II to increase progression-free survival for a group of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, the company reported Dec. 5 at the San Antonio Breast Cancer Symposium.

Women treated with PD-03392991 plus letrozole (Novartis AG’s Femara and generics) had a median progression-free survival of 26.1 months, a statistically significant increase over 7.5 months for letrozole alone,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

ClinicalTrials.gov Or ISRCTN: Getting Transparency Right For UK Trials

 
• By Vibha Sharma

ISRCTN’s systems are being redesigned to facilitate compliance with upcoming requirements in the UK’s clinical trials legislation.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.